
    
      This is a Phase 1, single-center, prospective, randomized, double-blind study of multiple
      ascending doses (MAD) of CD101 Injection administered IV to healthy adult subjects. In this
      study, subjects in 3 cohorts of 8 subjects each will be randomized to receive multiple IV
      doses of CD101 Injection or placebo infusions. Dose levels of CD101 Injection to be assessed
      will follow an ascending multiple-dose regimen.
    
  